ChromaDex appoints Gary Ng to Board, replaces Tony Lau as Champion River nominee

Niagen Bioscience, Inc.

Gary Ng appointed to Board effective Dec 13, 2021, to serve until 2022 annual meeting.
Ng replaces Tony Lau (resigned Nov 2, 2021) as Champion River Ventures' nominee under Purchase Agreement.
Ng receives $40k annual retainer, $7.5k for Compensation Committee, initial option for 40k shares vesting over 3 years.
Ng is Project Director at Horizon Ventures, which is affiliated with Champion River.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gary Ng

member of the Board

NAGE · Niagen Bioscience, Inc.

Effective: 2021-12-13
Successor: Tony Lau
Filed: December 13, 2021, 6:59 PM ET

On December 13, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) increased the size of the Board from eight to nine members and appointed Gary Ng as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Ng was appointed as member of the Board at Niagen Bioscience, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

On December 13, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) increased the size of the Board from eight to nine members and appointed Gary Ng as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-024959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.